Evaluating the influential factors of multidrug-resistant tuberculosis using a propensity score matching method

XU Ke; DING Song-ning; YANG Chen; WANG Rong; MIAO Rui-fen; ZHANG Da-wei; ZHANG Hong-ying; LI Chen

doi:10.16462/j.cnki.zhjbkz.2022.03.008

Volume 26 Issue 3

Mar. 2022

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2022 > 26(3): 285-289

XU Ke, DING Song-ning, YANG Chen, WANG Rong, MIAO Rui-fen, ZHANG Da-wei, ZHANG Hong-ying, LI Chen. Evaluating the influential factors of multidrug-resistant tuberculosis using a propensity score matching method[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(3): 285-289. doi: 10.16462/j.cnki.zhjbkz.2022.03.008

Citation:

XU Ke, DING Song-ning, YANG Chen, WANG Rong, MIAO Rui-fen, ZHANG Da-wei, ZHANG Hong-ying, LI Chen. Evaluating the influential factors of multidrug-resistant tuberculosis using a propensity score matching method[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(3): 285-289. doi: 10.16462/j.cnki.zhjbkz.2022.03.008

Citation:

XU Ke, DING Song-ning, YANG Chen, WANG Rong, MIAO Rui-fen, ZHANG Da-wei, ZHANG Hong-ying, LI Chen. Evaluating the influential factors of multidrug-resistant tuberculosis using a propensity score matching method[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(3): 285-289. doi: 10.16462/j.cnki.zhjbkz.2022.03.008

PDF( 991 KB)

Evaluating the influential factors of multidrug-resistant tuberculosis using a propensity score matching method

doi: 10.16462/j.cnki.zhjbkz.2022.03.008

Department of Chronic Infectious Disease Prevention and Control, Nanjing Municipal Center for Disease Control and Prevention, Nanjing 210003, China

Funds:

Medical Key Science and Technology Development Project of Nanjing Municipal Health Commission ZKX2019048

More Information

Corresponding author: LI Chen, E-mail: 24143179@qq.com
Received Date: 2021-03-29
Rev Recd Date: 2021-06-08

Available Online: 2022-03-17

Publish Date: 2022-03-10

Abstract

Abstract

Objective The aim of present study is to evaluate the influential factors of multidrug-resistance tuberculosis (MDR-TB) in Nanjing, and to provide scientific evidence for reducing the incidence rate of MDR-TB. Methods To screening 6 649 suspected MDR-TB cases who registered and managed in Nanjing from January 1, 2013 to December 31, 2020. The general information of the patients was checked through the Tuberculosis (TB) management system of the Chinese Center for Disease Control and Prevention, and the treatment management conditions of the patients were tracked through electronic medical records and telephone investigation. A total of 279 MDR-TB and 6 370 non-MDR-TB were described from general demographic characteristic. A total of 279 non-MDR-TB with 1∶1 matched were select using a propersity score matching method. Conditional Logistic regression model was used to analyze single and multiple factors influential of MDR-TB. Results Conditional Logistic regression results showed that previous history of second-line drugs and adverse reactions of anti-tuberculosis drugs were risk factors for MDR-TB (OR=2.39, 95% CI: 1.46-3.93, P < 0.001; OR=3.90, 95% CI: 2.45-6.21, P < 0.001), Initial treatment patient and regular medication were protective factors for MDR-TB (OR=1.55, 95% CI: 1.02-2.34, P=0.038; OR=2.63, 95% CI: 1.69-4.07, P < 0.001). Conclusions MDR causes a huge of harm to patients, their families and the society. Clinical medical institution and CDC should strengthen cooperation to improve the detection rate of TB and the standard treatment management rate of patients, so as to control the spread of MDR epidemic.
- Mycobacterium tuberculosis,
- Multidrug-resistance tuberculosis,
- Propensity score matching method,
- Influential factors

FullText(HTML)

References(14)

References

[1]	杨海涛, 陆伟, 竺丽梅. 耐药结核病的治疗与控制[M]. 北京: 军事医学科学出版社, 2014: 6-7, 145. Yang HT, Lu W, Zhu LM. Treatment and control of drug-resistant tuberculosis[M]. Beijing: Military Medical Science Press, 2014: 6-7, 145.
[2]	Daley CL, Caminero JA. Management of Multidrug-Resistant Tuberculosis[J]. Semin Respir Crit Care Med, 2018, 39(3): 310-324. DOI: 10.1055/s-0038-1661383.
[3]	World Health Organization. Global tuberculosis report 2018[R]. World Health Organization, 2018.
[4]	中国疾病预防控制中心专家组. 中国结核病预防控制工作技术规范(2020版)[M]. 北京: 人民卫生出版社, 2020: 18-19. Chinese Center for Disease Control and Prevention Expert Group. Technical Specifications for Tuberculosis prevention and control in China (2020 edition)[M]. Beijing: People's Medical Press, 2020: 18-19.
[5]	Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015[J]. Int J Tuberc Lung Dis, 2015, 19(11): 1276-1289. DOI: 10.5588/ijtld.15.0389.
[6]	王坚杰, 周美兰, 杜义祥等. 武汉市耐药/耐多药结核病影响因素分析[J]. 中华疾病控制杂志, 2017, 21(2): 164-167. DOI:10.16462/j.cnki.zhjbkz.201 7.02.014. Wang JJ, Zhou ML, Du YX, et al. Analysis on the influential factors of drug resistance and multidrug resistant tuberculosis in Wuhan City[J]. Chin J Dis Control Prev, 2017, 21(2): 164 - 167. DOI: 10.16462/j.cnki.zhjbkz.2017.02.014.
[7]	Gaude GS, Hattiholli J, Kumar P. Risk factors and drug-resistance patterns among pulmonary tuberculosis patients in northern Karnataka region, India[J]. Niger Med J, 2014, 55(4): 327-332. DOI: 10.4103/0300-1652.137194.
[8]	Matteelli A, Centis R, D'Ambrosio L, et al. WHO strategies for the programmatic management of drug-resistant tuberculosis[J]. Expert Rev Respir Med, 2016, 10(9): 991-1002. DOI:10.1080/1747634 8.2016.1199278.
[9]	Sun G, Luo T, Yang CG, et al. Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients[J]. J Infect Dis, 2012, 206(11): 1724-1733. DOI: 10.1093/infdis/jis601.
[10]	Misombo-Kalabela A, Nguefack-Tsague G, Kalla GC, et al. Risk factors for multidrug-resistant tuberculosis in the city of Kinshasa in the Democratic Republic of Congo[J]. Pan Afr Med J, 2016, 23: 157. DOI: 10.11604/pamj.2016.23.157.6137.
[11]	Stosic M, Vukovic D, Babic D, et al. Risk factors for multi- drug- resistant tuberculosis among tuberculosis patients in Serbia: a case-control study[J]. BMC Public Health, 2018, 18(1): 1114. DOI: 10.1186/s12889-018-6021-5.
[12]	Tupasi TE, Garfin AM, Kurbatova EV, et al. Factors associated with loss to follow- up during treatment for multidrug- resistant tuberculosis, the Philippines, 2012-2014[J]. Emerg Infect Dis, 2016, 22(3): 491-502. DOI: 10.3201/eid2203.151788.
[13]	Cox HS, Niemann S, Ismailov G, et al. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance[J]. Clin Infect Dis, 2007, 44(11): 1421-1427. DOI: 10.1086/517536.
[14]	杨小猛, 赵丹, 陈倩瑜, 等. 结核分枝杆菌L型感染对结核病患者耐药状况的影响[J]. 临床肺科杂志, 2015, 20(3): 426-429. DOI:10.3969 /j.issn.1009-6663.2015.03.013. Yang XM, Zhao D, Chen QY, et al. Effect of mycobacterium tuberculosis L form infection on drug resistant state in tuberculosis patients[J]. Clin J Pulmonary Med, 2015, 20(3): 426-429. DOI:10.3969 /j.issn.1009-6663.2015.03.013.